1. Home
  2. PMAX vs ANEB Comparison

PMAX vs ANEB Comparison

Compare PMAX & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$2.31

Market Cap

4.5M

Sector

N/A

ML Signal

HOLD

Logo Anebulo Pharmaceuticals Inc.

ANEB

Anebulo Pharmaceuticals Inc.

HOLD

Current Price

$1.70

Market Cap

96.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
ANEB
Founded
2019
2020
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
96.8M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
PMAX
ANEB
Price
$2.31
$1.70
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7M
21.7K
Earning Date
09-23-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,799,100.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.56
$0.80
52 Week High
$23.17
$3.42

Technical Indicators

Market Signals
Indicator
PMAX
ANEB
Relative Strength Index (RSI) 49.97 26.77
Support Level $2.17 $1.91
Resistance Level $2.36 $2.40
Average True Range (ATR) 0.31 0.15
MACD -0.04 -0.03
Stochastic Oscillator 12.71 8.88

Price Performance

Historical Comparison
PMAX
ANEB

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About ANEB Anebulo Pharmaceuticals Inc.

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.

Share on Social Networks: